CVD-REAL Results in More Diverse Countries Link SGLT2s to Lower Risk of Death, Heart Attack, Stroke

REAL, the giant study of real-world evidence comparing sodium glucose co-transporter-2 inhibitors with other glucose-lowering drugs to treat type 2 diabetes, found a 49% lower risk of all-cause death and a host of other benefits across 6 new, more diverse countries, the study's lead author told a packed room Sunday at the 67th Scientific Session of the American College of Cardiology in Orlando, Florida.